| D02714 | |
| D number | D02714 |
| Classification | Drug |
| Name | Everolimus (JAN/USAN/INN); Afinitor (TN); Votubia (TN); Zortress (TN) |
| Component | - |
| Formula | C53H83NO14 |
| Exact mass | 957.5814 |
| Mol weight | 958.2244 |
| Structural formula |  |
| Sequence | - |
| Sequence type | - |
| Source | - |
| Upper DGroup | Antineoplastic DG01597 mTOR inhibitor Cyp substrate DG01633 CYP3A substrate Transporter substrate DG01665 P-glycoprotein substrate |
| Remark | Therapeutic category: 3999 4291 ATC code: L01XE10 L04AA18 Pancreatic neuroendocrine tumor [DS:H00045] Renal cell carcinoma [DS:H00021] Renal angiomyolipoma with tuberous sclerosis complex (TSC) [DS:H01691] Subependymal giant cell astrocytoma (SEGA) with tuberous scleorosis complex (TSC) [DS:H01692] |
| Activity | - |
| Disease | - |
| Comment | Rapamycin derivative Indication: Advanced hormone receptor-positive, HER2-negative breast cancer, advanced neuroendocrine tumors of pancreatic origin, advanced renal cell carcinoma, tuberous sclerosis complex (TSC), subependymal giant cell astrocytoma with TSC |
| Target | MTOR [HSA:2475] [KO:K07203] |
| Metabolism | Enzyme: CYP3A4 [HSA:1576] Transporter: ABCB1 [HSA:5243] |
| Interaction | Genomic biomarker: HER2 [HSA:2064], ESR [HSA:2099 2100] |
| Other DBs | CAS: 159351-69-6 PubChem: 17396881 ChEBI: 68478 ChEMBL: CHEMBL1908360 LigandBox: D02714 |
| KCF data | - |